-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 GfLnWfIYZwBZ/2u8Z+4n+BIshFrP7v7TQSDrmCb+tQTmm2qreHLLsilwv/PA61Hm
 3GJOYtV6JnsPNmsbj3Hs2Q==

<SEC-DOCUMENT>0000890163-08-000517.txt : 20080709
<SEC-HEADER>0000890163-08-000517.hdr.sgml : 20080709
<ACCEPTANCE-DATETIME>20080709144816
ACCESSION NUMBER:		0000890163-08-000517
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080709
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20080709
DATE AS OF CHANGE:		20080709

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PIPEX PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		08944722

	BUSINESS ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108
		BUSINESS PHONE:		734-332-7800

	MAIL ADDRESS:	
		STREET 1:		3985 RESEARCH PARK DRIVE
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD MEDICAL TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19940606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>s11-8614_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE> </TITLE>
</HEAD>
<BODY bgcolor="#ffffff">




<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:center;'><b><font SIZE=5>UNITED STATES</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=5>SECURITIES AND EXCHANGE COMMISSION</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>WASHINGTON, D.C. 20549</font></b></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:center;'><b><font SIZE=5>FORM 8-K</font></b></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:center;'><b><font SIZE=2>CURRENT REPORT</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font SIZE=2>PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</font></b></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:center;'><font size=2>Date of Report (Date of earliest event reported): July 9, 2008</font></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:center;'><font size=2>Pipex Pharmaceuticals, Inc.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>(Exact name of registrant as specified in its charter)</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="106%" style='border-collapse:collapse'>
    <tr style=' height:39.2pt'>
        <td width="28%" valign=top style=' height:39.2pt'>
            <p style='margin-left:3.0pt;text-indent:-3.0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>Delaware</font></p>
<p style='margin-left:3.0pt;text-indent:-3.0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>(State or other jurisdiction of</font></p>
<p style='margin-left:3.0pt;text-indent:-3.0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>incorporation)</font></p> </td>
        <td width="29%" valign=top style=' height:39.2pt'>
            <p style='margin-left:.75pt;text-indent:0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>01-12584</font></p>
<p style='margin-left:.75pt;text-indent:0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>(Commission</font></p>
<p style='margin-left:.75pt;text-indent:0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>File Number)</font></p> </td>
        <td width="41%" style='height:39.2pt'>
            <p style='margin-left:.75pt;text-indent:0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>13-3808303</font><br> <font size=2>(IRS Employer</font></p>
<p style='margin-left:.75pt;text-indent:0pt;text-align:center;margin-top:0in;margin-bottom:0in'><font size=2>Identification Number)</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>3930 Varsity Drive</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>Ann Arbor, MI 48108</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>(Address of principal executive offices) (Zip Code)</font></b></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:center;'><font size=2>(734) 332-7800</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><b><font size=2>(Registrant's telephone number, including area code)</font></b></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:left;'><font size=2>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:</font></p>

<p style=' margin-bottom:0pt; margin-top:11.25pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="101%" style='border-collapse:collapse'>
    <tr style='height:13.9pt'>
        <td width="5%" valign=top style=' height:13.9pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>|_|</font></p> </td>
        <td width="94%" valign=top style=' height:13.9pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></p> </td> </tr>
    <tr style='height:13.15pt'>
        <td width="5%" valign=top style=' height:13.15pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>|_|</font></p> </td>
        <td width="94%" valign=top style=' height:13.15pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p> </td> </tr>
    <tr style='height:27.8pt'>
        <td width="5%" valign=top style=' height:27.8pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>|_|</font></p> </td>
        <td width="94%" valign=top style=' height:27.8pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act </font><br> <font size=2>(17 CFR 240.14d-2(b))</font></p> </td> </tr>
    <tr style='height:27.05pt'>
        <td width="5%" valign=top style=' height:27.05pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>|_|</font></p> </td>
        <td width="94%" valign=top style=' height:27.05pt'>
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:6.0pt'><font size=2>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act </font><br> <font size=2>(17 CFR 240.13e-4(c))</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:12pt; margin-top:0pt;text-align:left;'><b><font size=2>Item 8.01 Other Events.</font></b></p>

<p style=' margin-bottom:5pt; margin-top:5pt; text-indent:0.54in;text-align:justify;'><font size=2>On July 9, 2008, the Registrant issued a press release announcing results and publication for positive double-blind, placebo-controlled clinical trial results in the treatment of dry age-related  macular degeneration with oral Zinthionein( (formerly Z-Monocys, zinc-monocysteine) meeting all global central retinal function measurements of the clinical trial.  The press release is furnished as an exhibit to this current report. </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="96%" style='border-collapse:collapse'>
    <tr >
        <td width="17%" valign=top >
            <p style='margin-left:5.4pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><b><font size=2>Item 9.01</font></b></p> </td>
        <td width="82%" valign=top >
            <p style='margin-left:5.4pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><b><font size=2>Financial Statements and Exhibits</font></b></p>
<p style='margin-left:5.4pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <td width="17%" valign=top >
            <p style='margin-left:5.4pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>(d)</font></p> </td>
        <td width="82%" valign=top >
            <p style='margin-left:5.4pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Exhibits</font></p>
<p style='margin-left:5.4pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <td width="17%" valign=top >
            <p style='margin-left:5.4pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><u><font size=2>Exhibit No.</font></u><u></u></p> </td>
        <td width="82%" valign=top >
            <p style='margin-left:5.4pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><u><font size=2>Description</font></u></p>
<p style='margin-left:5.4pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></p> </td> </tr>
    <tr >
        <td width="17%" valign=top >
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:12.0pt'><font size=2>99.1</font></p> </td>
        <td width="82%" valign=top >
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:12.0pt'><font size=2>Press Release  </font></p> </td> </tr>
    <tr >
        <td width="17%" valign=top >
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:12.0pt'><font size=1>&nbsp;</font></p> </td>
        <td width="82%" valign=top >
            <p style='margin-left:5.75pt;text-indent:0pt;text-align:left;margin-top:0in;margin-bottom:12.0pt'><font size=1>&nbsp;</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:12pt; margin-top:6pt;text-align:center;'><font SIZE=2>SIGNATURE</font></p>

<p style=' margin-bottom:12pt; margin-top:0pt; text-indent:0.5in;text-align:left;'><font size=2>Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="263" style='margin-left:3.5in;border-collapse:collapse'>
    <tr >
        <td width="100%" valign=top style='padding:0in 0in 12.0pt 0in'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font SIZE=2>PIPEX PHARMACEUTICALS, INC.</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="508" style='border-collapse:collapse'>
    <tr >
        <td width="56%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Dated: July 9, 2008</font></p> </td>
        <td  colspan="3" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>By:  </font><u><font size=2>/s/ Nicholas Stergis</font></u></p> </td>
        <td width="4%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><u><font size=2>.</font></u></p> </td>
        <td  width="0%">
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></td> </tr>
    <tr >
        <td   colspan="2">
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></td>
        <td width="24%" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Nicholas Stergis</font></p> </td>
        <td   colspan="3">
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></td> </tr>
    <tr >
        <td   colspan="2">
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=1>&nbsp;</font></td>
        <td  colspan="4" valign=top >
            <p style='margin-left:0pt;text-indent:0pt;text-align:left;margin-top:0pt;margin-bottom:0pt'><font size=2>Chief Executive Officer</font></p> </td> </tr>
    <tr>
        <td width="288" ></td>

        <td width="48" ></td>

        <td width="124" ></td>

        <td width="20" ></td>

        <td width="24" ></td>

        <td width="4" ></td> </tr> </table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>



</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>s11-8614_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE> </TITLE>
</HEAD>
<BODY bgcolor="#ffffff">




<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><img src="intimg1.jpg"><br> </p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:3pt; margin-top:12pt;text-align:center;'><b><font size=5>Pipex Pharmaceuticals Announces Results of Eighty Patient, Six Month, Prospective, Randomized, Double-Blind Clinical Trial of Oral Zinthionein for Dry Age-Related Macular Degeneration (AMD)</font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><i><b><font size=3>Highly Statistically Significant Improvement in </font></b></i></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><i><b><font size=3>Visual Acuity (p&#60;0.0001),</font></b></i></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><i><b><font size=3>Contrast Sensitivity (p&#60;0.0001), </font></b></i></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><i><b><font size=3>and Photorecovery Time (p&#60;0.0001) at 6 Months</font></b></i></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=3>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><i><b><font size=3>Study Meets All Global Central Retinal Function Measurements</font></b></i></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=3>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><i><b><font size=3>Peer Review Results Published</font></b></i></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><font size=3>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:center;'><i><b><font size=3>Webcast/Conference Call at 10:15am EST </font></b></i></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Ann Arbor, Michigan, July 9, 2008 -- Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous system and autoimmune diseases, today announced results and publication of positive double-blind, placebo-controlled clinical trial results in the treatment of dry age-related macular degeneration (AMD) with oral Zinthionein&#153; (formerly Z-Monocys, zinc-monocysteine), meeting all global central retinal function measurements of the clinical trial.  Dry AMD is the leading cause of blindness in the U.S., affecting approximately 10 million Americans and has no FDA approved therapy.  </font></p>

<p style=' margin-bottom:5pt; margin-top:5pt;text-align:justify;'><font size=2>In order to participate in the webcast/conference call, please call toll free:</font><b><font size=2> </font></b><font size=2>(US): 800-952-4972; international dial-in: 416-641-2140, conference ID: Pipex.</font><b><font size=2>  </font></b><font size=2>A visual presentation will be available at: http://www.visualwebcaster.com/event.asp?id=49757.  The audio recording and visual presentation will be available for replay at http://www.pipexinc.com for a period of at least 15 days after the call.  </font></p>

<p style=' margin-bottom:5pt; margin-top:5pt;text-align:justify;'><font size=2>After six (6) months, compared to placebo treated patients, Zinthionein treated patients demonstrated a highly statistically significant improvement in visual acuity (p&#60;0.0001), contrast sensitivity (p&#60;0.0001) as well as photorecovery time (p=0.0001), each of which </font></p>

<p style=' margin-bottom:0pt; margin-top:5pt;text-align:justify;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:5pt; margin-top:5pt;text-align:justify;'><font size=2>represent carefully measured endpoints of global central retinal function that is compromised in AMD.  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>The following table represents the results of the visual acuity endpoint as measured by ETDRS on a per eye basis at month 6:</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="98%" >
    <tr >
        <td width="27%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Eye</font></p> </td>
        <td width="34%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Change from </font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Baseline  at 6 months (Mean &#177; SEM) </font></p> </td>
        <td width="37%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>6 month </font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>(Placebo vs. Zinthionein therapy)</font></p> </td> </tr>
    <tr >
        <td width="27%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Right (Zinthionein group)</font></p> </td>
        <td width="34%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>4.405+/- 0.712</font></p> </td>
        <td width="37%" rowspan=2 valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>p&#60;0.0001</font></p> </td> </tr>
    <tr >
        <td width="27%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Right (Placebo )</font></p> </td>
        <td width="34%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>-1.054 &#177; 0.489</font></p> </td> </tr>
    <tr >
        <td width="27%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Left (Zinthionein group)</font></p> </td>
        <td width="34%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>3.057 +/- 0.639</font></p> </td>
        <td width="37%" rowspan=2 valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>p&#60;0.0001</font></p> </td> </tr>
    <tr >
        <td width="27%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Left (Placebo )</font></p> </td>
        <td width="34%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>-0.703 &#177; 0.642</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>The following table represents the results of the contrast sensitivity endpoint of the study on a per eye basis at month 6:</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="98%" >
    <tr >
        <td width="25%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Eye</font></p> </td>
        <td width="37%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Change from </font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Baseline  at 6 months (Mean &#177; SEM)</font></p> </td>
        <td width="37%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>6 month </font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>(Placebo vs. Zinthionein therapy)</font></p> </td> </tr>
    <tr >
        <td width="25%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Right (Zinthionein group)</font></p> </td>
        <td width="37%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>0.199 &#177; 0.045</font></p> </td>
        <td width="37%" rowspan=2 valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>p&#60;0.0001</font></p> </td> </tr>
    <tr >
        <td width="25%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Right (Placebo )</font></p> </td>
        <td width="37%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>-0.039 &#177; 0.029</font></p> </td> </tr>
    <tr >
        <td width="25%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Left (Zinthionein group)</font></p> </td>
        <td width="37%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>0.159 &#177; 0.029</font></p> </td>
        <td width="37%" rowspan=2 valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>p&#60;0.0001</font></p> </td> </tr>
    <tr >
        <td width="25%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Left (Placebo )</font></p> </td>
        <td width="37%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>-0.035 &#177; 0.025</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>The following table represents the results of the photo recovery time endpoint of the study on a per eye basis at month 6:</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>


<table border="0" cellspacing=0 cellpadding=0 width="98%" >
    <tr >
        <td width="25%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Eye</font></p> </td>
        <td width="37%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Change from </font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Baseline  at 6 months (Mean &#177; SEM)</font></p> </td>
        <td width="37%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>6 month </font></p>
<p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>(Placebo vs. Zinthionein therapy)</font></p> </td> </tr>
    <tr >
        <td width="25%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Right (Zinthionein group)</font></p> </td>
        <td width="37%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>-7.351 &#177; 0.911</font></p> </td>
        <td width="37%" rowspan=2 valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>p&#60;0.0001</font></p> </td> </tr>
    <tr >
        <td width="25%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Right (Placebo )</font></p> </td>
        <td width="37%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>0.189&#177; 0.673</font></p> </td> </tr>
    <tr >
        <td width="25%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Left (Zinthionein group)</font></p> </td>
        <td width="37%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>-7.171 &#177; 1.149</font></p> </td>
        <td width="37%" rowspan=2 valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>p&#60;0.0001</font></p> </td> </tr>
    <tr >
        <td width="25%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>Left (Placebo )</font></p> </td>
        <td width="37%" valign=top style='padding:0in 5.4pt 0in 5.4pt'>
            <p style='margin-left:0pt;text-indent:0pt;text-align:center;margin-top:0pt;margin-bottom:0pt'><font size=2>0.541 &#177; 0.597</font></p> </td> </tr></table>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Zinthionein appeared to be well tolerated in the study, with only a two percent (2%) gastrointestinal irritation rate as compared to placebo.  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>David A. Newsome, M.D., a board certified ophthalmologist, former Head of the Retinal Disease Section of the National Eye Institute (NEI), co-inventor of Zinthionein, primary investigator of the clinical trial, and a scientific advisor to Pipex commented, &#147;I believe these results are striking in that significant dry AMD improvement can be achieved rapidly with Zinthionein.  It is very rare for a phase II Dry AMD study to demonstrate significance on all of the measurements of global retina function with strong statistical significance.  I look forward to continued collaboration with the Pipex team to further develop Zinthionein as a potential new therapy for Dry AMD.&#148;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Nicholas Stergis, Chief Executive Officer of Pipex, commented, &#147;We are pleased to report these results and we believe this is a significant step forward for the 10 million Americans affected with Dry AMD whose therapeutic options are limited.  Zinthionein builds upon Dr. Newsome&#146;s original hypothesis of zinc deficiency in AMD, which formed the basis for the National Eye Institute&#146;s successful Age-Related Eye Disease Study (AREDS), the largest study ever conducted in AMD and which confirmed a protective role for zinc in AMD.  In addition to providing zinc, Zinthionein incorporates Dr. Newsome&#146;s more recent hypothesis of supplying the retina with a metabolically active form of cysteine as a necessary precursor to boost the potent retinal antioxidant system, glutathione (GSH), considered by Dr. Newsome to be the second most important protective system against oxidative free radicals present
in the retinal pigment epithelium (RPE) and other retinal tissues.  The combination of these important features may make Zinthionein an important new treatment option for Dry AMD patients as well as additional important indications which also may involve metal dyshomeostasis that we are currently exploring.&#148; </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Mr. Stergis continued, &#147;We look forward to reporting additional data from studies conducted with Zinthionein, along with our commercialization plans for this compound.&#148; </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Zinthionein Capsules</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Zinthionein Capsules (oral zinc-monocysteine) is a novel composition-of-matter patent protected complex of zinc and cysteine, ingredients which are currently generally regarded as safe (GRAS).    Zinthionein  is covered by issued U.S. patents 7,164,035 and 6,586,611 which provide composition-of-matter protection through the year 2020 (or 2025 with patent term extension, if available) as well as additional pending U.S. and international  patent applications. For further information on Zinthionein, please review the below references (1),(2).  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>About the Clinical Trial Design</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Zinthionein capsules (25mg capsules twice daily) were compared to placebo capsules twice daily on a 1:1 randomization scheme in a prospective, randomized, double-blind, placebo-controlled trial involving a total of 80 Dry AMD patients for period of six (6) months at a single site.  All patients had drusen, including medium size drusen.  Patients displaying signs of choroidal neovascular activity (i.e. the wet form of AMD) were excluded.  The average age of participants 73.3 years of age in Group 1 (placebo) and </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>72.1 years of age in Group 2 (Zinthionein). Functional assessment included best-corrected visual acuity determined by blinded trained examiners using an internally lighted ETDRS logMar chart and ETDRS procedures.  Visual acuity was recorded as number letters correctly identified with best correction.  Contrast sensitivity was determined at 1 meter using a calibrated Pelli Robson chart in 85 cd/m</font><sup><font size=2>2</font></sup><font size=2> lighting also with best correction using standard methodology.  Results were recorded as the log contrast sensitivity from the Pelli Robson alogorithm.  Photorecovery times were determined using a device invented by Dr. Newsome (U.S. Patent 6,863,399) that delivered a reproducible bleaching flash to the macula with built-in verification to assure that the subject correctly identified the endpoint stimulus.  Results were recorded as seconds (time) required to
recover from a flash-induced glare sufficiently to identify new stimuli presented by the device. Reprints of the complete study details, demographics and clinical macular characteristics of subjects and detailed results are available in the publication are available online for immediate download from the publisher in the July issue of the peer-reviewed ophthalmology journal, </font><i><font size=2>Current Eye Research </font></i><font size=2>(1).  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><b><font size=2>About Pipex Pharmaceuticals, Inc. </font></b></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>Pipex Pharmaceuticals, Inc. is a specialty pharmaceutical company that is developing proprietary, late-stage drug candidates for the treatment of central nervous system and autoimmune diseases.  Pipex&#146;s strategy is to exclusively in-license proprietary, clinical-stage drug candidates and to complete the further clinical testing, manufacturing and regulatory requirements and seek marketing authorizations.  Pipex is focused on treating Dry Age-Related Macular Degeneration (AMD), multiple sclerosis (MS), and fibromyalgia.  For further information, please visit www.pipexinc.com.  </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.71in;text-align:justify;'><font size=2> (1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Newsome DA, A Randomized, Prospective, Placebo-Controlled Clinical Trial of a Novel Zinc-Monocysteine Compound in Age-Related Macular Degeneration, Current Eye Research, Vol. 33, Iss. 7 July 2008 pp. 591:598.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt; text-indent:0.5in;text-align:justify;'><font size=2>(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tate DJ, Newsome DA, A novel zinc compound (zinc-monocysteine) enhances the antioxidant capacity of human retinal pigment epithelial cells. Curr Eye Res. 2006 Jul-Aug;31(7-8):675-83.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Pipex's commercialization plans for its product candidates.  Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Pipex is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Pipex's forward-looking statements include, among others, a failure of Pipex's product
candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to </font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>&nbsp;</font></p>
<br>
<HR noshade align="center" width="100%" size="2">
<p style='page-break-before:always'></p>
<pAGE>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:justify;'><font size=2>comply with ongoing regulatory requirements, a lack of acceptance of Pipex's product candidates in the marketplace, a failure of the company to become or remain profitable, Pipex's inability to obtain the capital necessary to fund its research and development activities, a loss of any of the company's key scientists or management personnel, and other factors described in Pipex&#146;s report on Form 10-Q for the quarter ended March 31, 2008.  No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Pipex undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>For Further Information Contact:</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Nicholas Stergis</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Chief Executive Officer</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>(734) 332-7800</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Redington, Inc. (Investor Relations)</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>Thomas Redington</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>203-222-7399</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>www.redingtoninc.com</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>&nbsp;</p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>


<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'><font size=2>&nbsp;</font></p>

<p style=' margin-bottom:0pt; margin-top:0pt;text-align:left;'>&nbsp;</p>



</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>intimg1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 intimg1.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`!E`9(#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB
M@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBDH`6BBB@`HI,TM`!245Y=K_B#
M4[75M2CBU:>)(IF5%$B@(.P`Q32N-*YZC2U#:,7M(F8Y+1J2?4XJ6D(6BBB@
M`HHI*`%HI*6@`HI**`%HHHH`****`"BBB@`HHI*`%HI*6@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"D/2EHH`\U\4S3Q
M^);T?:+Y4PFQ8GD"CY1G&.*PVN[T$XNM1QGC+RU[+15<WF_Z^12=CQ@7>H$$
M_:M1QZ^9+0;F^(R;C43C_;EKV>BCF\W^'^0^;R1Y'IVNZO:S#[-JLS,O6&X8
MNGX@\BO1O#NO1ZY9%]GDW$1V3PY^Z?4>Q[51\::9;W&B37I15N;;$B2`8/7E
M2>X-8'A"5HO%"!3@7-LP<8ZE<$'^?YU-VWJ2VKGH=>4>(9)EU756%U*ICG;:
M!C';U%>KUY!XC/\`Q/M4'3]^_-5'3\/S'%7/6;0?Z+$3U,:Y_*LGQF7'AFZ,
M9D#`I@QYW??'IS6O:?\`'G#_`-<U_E4M3LR3QN1[C.(SJ9SZ^;4>;XC'_$Q/
M4X_>FO:**KF\W^'^12E9;'BY6^X.W4.?:6@7%Y;.KM/?6Y)^^9)$_G7M%-EC
M26-DD4,C<%6&0?PHYO-_A_D/G\D<#H7C"]M)88M5E^TVDA"BY;`:+/0MCJ/?
MJ*]`!R`:\NUW38+#6;ZP@1?L[('5,_<W#I],UWOAFX>Z\-Z?-*27:!02>IQQ
MG]*B_<B^I4\3^(QHT4<%NJRWL^3&K'Y44=6;V_G7GE]JNIWLY6XU"YN'/_+.
M-R%_!5K3\23LWB/5;@@DP[(ESV`7/\R36V^_PQX,M[O3?*%U.T9EF=-V_=R?
MP]*I7YK(J+78X@V5YP&L]0XY^Y+2BQO>UE??]^I:W)/&GB*-MIN[5AZBW_\`
MKTS_`(3CQ#_S]6Y_[=__`*]/F7\WX_\``-?>[(R([&Y8YDL=1Y](Y:Z;P5:O
M%XBW?9KR)/L[`F9'`SD?WJJ1^,_$4K8%W;*!_P!,!_C6WX7\0ZKJ.M?9+VY@
MFB\AG_=Q;><COGWHYD[I2O\`/_@&4[WUT.NGR;>3&<[#_*O(8M/E:V02Z=J9
MDQ\Q6*7`->Q45*;2T9)XV^FW>1Y>GZ@5]X9:2*YOM+E'E3WEC*?X6+J6/T;K
M7LM5-4L+;4K"6VN4#(RG!(Y4]B/0BFF^[-.?R.`E\=:M)IHME$:7!.&NE')7
MV7H&_2L(M>:G,SE[V^D'#,N^3'Y=*9;Q"YN+>W+8$LJQ,X/(!8`D?G7LEK:P
MV<"06\:QQ(,*JC`%',_3T')J.R/(UL+I0-^G:GQTVP3?X58M["=;NV\K3]25
MA/'DO%*!C<,YKUNDI)M.]V9MW"EHHH$%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%(>E+24`<HWC^T5W4:;?,$9EW`)@X./[U1GXC6`ZZ
M;?#'7A/_`(JN296=C&K[/,NRF['(!?']:Z5OAPS]=:;G_IV'^-/J]/Q_X`XV
M>Y8/Q&T\?\PZ]_)/_BJ0?$>Q)P--O/K\G_Q55_\`A6[?]!EO_`8?_%4O_"M^
M>=88CT%LO^-'R7WO_(NT#,UWQ5<:[#]D2W^R698,^Y\N^.@/8#-:G@73GFN9
M=892L'E^3;YXWC/S-].`!^-7+'P!IEM(LES+/=D?P.0J$_0=?Q-=2D:QJ%10
MJ@8``P`*1#MT%KR'Q(K'6]48=!.^:]>KDM0\"G4+VZN#JLD0N7+F,0@@9[9S
M37^0)V.HM/\`CSA_ZYK_`"K.U[Q!%H2P-):S7!G8JJQ8R,#/<BM.&/RHDCSG
M:H&?H*Y/QZ,MI8QG]\__`*#2\R7H@/Q$M5X;2KU?KL_^*I#\1[(?\PV\/XI_
MC6'H?AK_`(2+[6S7\MN+>4(%$88'(SFM<?#:(==6E/\`VQ6GZI?>_P#(T7);
M4D'Q'LO^@9>?FG^-07'Q(C92MKI4I<C@S2*%!^@R:?\`\*WB/75I_P#OTM/C
M^&]HK`R:E=,!V157^E._DOO?^0>X<KF]U:_=!B?4;YL97@(/7V4"O5+"SCL+
M"WM(LE(8P@)ZG`ZU5TG0-/T6-ELX2'<?/*YW.WU/]*TA4D.W0\_\::<UCJK:
MEM_T2\`25L?<D`P,^Q%9UIXA%KIPTG4].34[*,@QC=M91U`]#CMTKTZ:".XB
M:*9%DC<89&&01[BN8N?A]I4DC/;RW-J"<[$<,@^@(/\`.A:.XUR]3FQJ_A4C
MY?"7_CZ_XT'6/"PZ>$S_`-]K_C6Z/AU:CKJ5U_WRG^%'_"N;3_H)77_?*?X5
M7,_Z;_R+]SS,0:KX:887PCN]A*O^-;7A:]TB;63%9^'SI\YA+>87!RN1QP?\
MXIP^'ENOW=5NQ_P%/\*T=%\)Q:-?_;$OIYV\LQA9`N`"1Z#VHYN_ZD.W0WI'
MV1LW7:,XKC5^(>^,.NB7)4]#YJ<UV4B[T9>FX8KD5^'L"(J+JUX%7H,)_A4K
M81$?B,BG#:-.#[S)6;J_CF\U&UDM;2U%HDBE6D,F]\'TQP*U_P#A7EH1SJ5V
M?J$_PJ6#X>Z4CAIYKJX`ZJSA5/UV@']:=_3\2_</.\#8/O",G:K@$#([`^HK
MKK'X@WMM"L-[8K=,H`\V.78S>Y!'6NTDTC3Y=/&GO9PFU`P(MN`/IZ'WK`E^
M'FENY:*YNX03D*'5@/;D9J5IM^(^92^(K+\10_W=&F/_`&V6I$\?%IHHWT>6
M,22*FXSJ<9.,TX?#NQ7IJ-Z/H4_PJ:/P)9QRQN;^\?RW5P&*X)!R.U5UUM^)
M#MT.HI:2EI""BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MD-+2$9H`\E4$3QYR/]/Z'_KI7K588\&:$)_.%FP</Y@/FO\`>SG.,^M;@Z4W
M;\Q)6%HHHI#"BBB@`HHHH`*Y#QYR=,P"?WS=/]VNOJAJFBV&LI&E_!YRQG*C
M>RX/X$4":NK'/?#_`#LU3@?\?"_^@BN@UN_DTS29;N+RPR%`#+G:,L%R<=AG
M-+I>C6&C)(EA!Y*RMN<;RV3T[FIK^RCU"T:VE8A&96)'^RP;^E.ZN5&R:N9^
ME:O/>?;T<V\XM<;;BWSY<F03CDGD8YY/45#I_B>'4)=+AB9&ENT+3*%8;,)N
MXS[\5N-$K1-&!M5@1QVS5.+2HHET]1)(?L"[8\D?-\NWG\*=XE7CKH5=1UM[
M+6K2S6.-H'*BXD+8,>\E8\#W88--US69--O+:!;FSM4ECD=I;H$CY=O`P1Z_
MI4MWX<L+XW<EQ'OGN2")BHWQ8`"[#CC!&?K5N73XI[R*YE)8QQ/%M(&&#8SG
M\J?NZ#O'0SI=:O?^$2&K16B"[9%*0N2%8E@H]\'.1]:C;Q(TM[I$-K"K1WH!
MG+$YB!5L`>^58?@:T!I,8TB/3#-*T<>T*Y(W85@0/T`J&#PY9V]P9HVD#&[^
MU8)R`VTC:/1?F)QZFB\1IPU&ZOK;Z=J%I`D<;1N0URS-@QH6"J1_P(_D#4VI
M7US'?6NGV2Q">X5Y#)*"51$QG@$9.6`ZTV\\/:?J$MU+=Q":2X0('903$`.-
MIQQR2?K4EWI?VD6TB74L-U:@A)U`)((PP((P0<#\0*/=T%[NA!?ZE>Z?X?DO
M;B&&*YB(5@26CY<+NXYQ@YQUJ2POII]/FNGN+:X"`[&@C9!P.AR32R:,DFCM
MIQN9\LP<SL0SEMV[//'4=,8JQ;6LT<4D=U>/=A^/G15P/3Y0*6EA75BI;ZK+
M,-))C0?;XB[XS\I"!N*:+K5/[?-D7M/LXB\[/EMOV[L8SNQGWIUCH@LYH'>\
MFN$M4*6Z.%`C!XZ@<G`QDU<^QI_:1OMS;S#Y6WMC.<T:`W%;$<-Z\FL75D44
M)!#%(&[DL7!_]!%4M/U'5+_R;V."W-C-*RA,D2J@)`<G.#R/NXZ'K6C'9)'J
M,]Z&8O/&D;*>@"EB,?\`?1JE!H*P7"%+R<6L4IFCM00%5CD]<9(R2<9Q1H%X
MC=1UM[+6+2T6.-H7(^T.S8,>\[8\#W8<U;FO'CU>VLPJE)HI'+=P5*X_]"JM
M>>'+"^:[DN(P\USC$Q4;XL`!=AQQ@C/UJ:]TR2ZN;>YBO9;::!&0,B*VX-C.
M00?[HH]T/=T(=>U2?2X[=HE1(Y9"LMQ)&SI",$@D+SR>,]!5K2[MK[3X[AWM
MY"^?GMWW(W/4'^G:DNK":>.`QW\T,\/_`"U0##Y&#N7&#_2ETW3HM,M3#&[.
M7D:1W;&6=CDG`X'/84:6!VY?,MTM%%20%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
B444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`'__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
